{"eu_number": "EU-3-00-005", "parse_date": "2022-11-29 19:27:18.390225", "decisions": [{"filename": "EU-3-00-005_o_dec_0.pdf", "eu_aut_date": "2000-10-18 00:00:00", "eu_brand_name_initial": "Gemtuzumab Ozogamicin", "eu_brand_name_current": "Not parsed", "eu_od_initial": "adopted", "eu_mah_initial": "the sponsor: Wyeth Europa Limited", "eu_mah_current": "Not parsed", "eu_od_comp_date": "1900-01-01 00:00:00"}, {"filename": "EU-3-00-005_o_dec_1.pdf", "eu_aut_date": "2013-03-15 00:00:00", "eu_brand_name_initial": "Gemtuzumab Ozogamicin", "eu_brand_name_current": "Not parsed", "eu_od_initial": "Not parsed", "eu_mah_initial": "Not parsed", "eu_mah_current": "Wyeth Europa  Limited", "eu_od_comp_date": "1900-01-01 00:00:00"}, {"filename": "EU-3-00-005_o_dec_2.pdf", "eu_aut_date": "2018-07-25 00:00:00", "eu_brand_name_initial": "Gemtuzumab Ozogamicin", "eu_brand_name_current": "Not parsed", "eu_od_initial": "Not parsed", "eu_mah_initial": "Not parsed", "eu_mah_current": "Pfizer Limited", "eu_od_comp_date": "1900-01-01 00:00:00"}], "annexes": [], "epars": [{"filename": "EU-3-00-005_o_public-assessment-report", "ema_procedure_start_initial": "1/12/2016", "chmp_opinion_date": "22/02/2018", "eu_legal_basis": ["article 8.3"], "eu_prime_initial": "no", "ema_rapp": "nithyanandan nagercoil", "ema_corapp": "sinan b. sarac", "ema_reexamination": "no", "eu_accel_assess_g": "no"}], "omars": [{"pdf_file": "EU-3-00-005_o_omar.pdf", "xml_file": "EU-3-00-005_o_omar.xml", "creation_date": "D:20180423134121+01'00'", "modification_date": "D:20180423134124+01'00'", "ema_omar_condition": [{"eu_od_number": "eu/3/00/005", "ema_prevalence": "the prevalence of acute myeloid leukaemia (hereinafter referred to as \u201cthe condition\u201d) was estimated to remain below 5 in 10,000 and was concluded in to be approximately 1 in 10,000 persons in the european union, at the time of the review of the designation criteria; ", "ema_alternative_treatments": "significant_benefit", "ema_significant_benefit": "it was demonstrated that the addition of mylotarg to authorised induction chemotherapy with daunorubicin and cytarabine led to improved event-free survival when compared to standard chemotherapy alone."}]}]}